Viatris (VTRS) Income from Continuing Operations (2019 - 2026)
Viatris (VTRS) recorded quarterly Income from Continuing Operations of 176400000.0 in Q1 2026, up 151.87% quarter-over-quarter from 340100000.0 in Q4 2025, and up 105.8% on a YoY basis from 85714778.61 in Q1 2025.
Viatris (VTRS) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Viatris' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 176400000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 105.8% year-over-year to 176400000.0; the TTM figure through Mar 2026 stood at 296500000.0 (up 92.18% YoY), while the FY2025 annual figure was 3514900000.0, down 454.23% from the prior year.
- Income from Continuing Operations was 176400000.0 for Q1 2026 at Viatris, up from 340100000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1011200000.0 in Q4 2022 to a low of 3042000000.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 103747058.82 across 5 years, with a median of 113900000.0 in 2024.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations jumped 483.32% in 2022, then slumped 2770.76% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 1011200000.0 in 2022, then plunged by 175.71% to 765600000.0 in 2023, then surged by 32.54% to 516500000.0 in 2024, then jumped by 34.15% to 340100000.0 in 2025, then jumped by 151.87% to 176400000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 176400000.0 (Q1 2026), 340100000.0 (Q4 2025), and 128200000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Viatris | - | - | 1.16 Bn | 176.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 176.40 Mn |
| Dec 31, 2025 | -340.10 Mn |
| Sep 30, 2025 | -128.20 Mn |
| Jun 30, 2025 | -4.60 Mn |
| Mar 31, 2025 | -3.04 Bn |
| Dec 31, 2024 | -516.50 Mn |
| Sep 30, 2024 | 94.80 Mn |
| Jun 30, 2024 | -326.40 Mn |
| Mar 31, 2024 | 113.90 Mn |
| Dec 31, 2023 | -765.60 Mn |
| Sep 30, 2023 | 331.60 Mn |
| Jun 30, 2023 | 264.00 Mn |
| Mar 31, 2023 | 300.40 Mn |
| Dec 31, 2022 | 1.01 Bn |
| Sep 30, 2022 | 354.30 Mn |
| Jun 30, 2022 | 313.90 Mn |
| Mar 31, 2022 | 399.20 Mn |
| Dec 31, 2021 | -263.80 Mn |
| Sep 30, 2021 | 311.50 Mn |
| Jun 30, 2021 | -279.20 Mn |